Abstract：Objective: To observe the effect of pidotimod on immune and inflammatory factors of children with mycoplasma pneumonia.Methods: 80 cases of children with mycoplasma pneumonia treated in our hospital from March 2013 to July 2015 were selected and divided into control group and observation group according to random stratified grouping method, 40 cases in each group. The control group was given Azithromycin for treatment, while the observation group was given pidotimod on the basis of the treatment in the control group, then the level changes of immune function and inflammatory factors in the two groups were compared. Results: After treatment, immune function detecting indexes (IL-10,IL-6,TNF-α)in the observation group were all lower than those in the control group (t=5.731,P<0.05, inflammatory factor(CD3+,CD4+,CD8+,CD4+/CD8+)level in the observation group were all higher than those in the control group(t=5.538,P<0.05), CD8+ level in the observation group was lower than that in the control group(t=5.652,P<0.05). Conclusion: Clinical application of pidotimod for the treatment on children with mycoplasma pneumonia can improve the body's inflammatory status and immune function.
陈彦伶, 吴善姬. 匹多莫德对支原体肺炎患儿免疫及炎性因子的影响[J]. 河北医学, 2017, 23(3): 377-379.
CHEN Yanling, et al. Effect of Pidotimod on Immune and Inflammatory Factors of Children with Mycoplasma Pneumonia. HeBei Med, 2017, 23(3): 377-379.
2017, Vol. 23 
冀公网安备13080202000677号